Mainz Biomed N.V.’s eAArly DETECT study produced positive topline results.Â
Long-term follow-up data from the phase III KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment showed that a statistically significant and clinically meaningful improvement in overall survival, a secondary endpoint, was observed with adjuvant Kadcyla (ado-trastuzumab emtansine) compared to Herceptin (trastuzumab).
The phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) as a first-line treatment for people with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer showed positive results.Â
Data from the phase III PERSEUS study showed that a Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based quadruplet induction, consolidation regimen and doublet maintenance regimen showed clinical improvement in the treatment of transplant-eligible newly diagnosed multiple myeloma.Â
Patients treated with first-line immunotherapy for advanced non-small cell lung cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance, a study published in the Journal of the National Comprehensive Cancer Network showed.
Vanderbilt researchers led a clinical trial combining atezolizumab (Tecentriq), an immunotherapy, in combination with chemotherapy in patients with metastatic triple-negative breast cancer to both evaluate the efficacy of the treatment combination and to understand biomarkers of response to immunotherapy.
A decision-making aid to help women at high risk of breast cancer decide whether to add MRIs to their screening regimen has proved popular with both patients and doctors alike in early testing.
A team of Wistar researchers led by Hildegund C.J. Ertl—a professor in The Wistar Institute’s Vaccine & Immunotherapy Center—has demonstrated that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors. The study was published in Molecular Therapy Oncolytics.
Cedars-Sinai investigators have discovered how the liver defends itself against cancer. Their study, published in the peer-reviewed Journal of Hepatology, suggests targets for therapies to protect the liver both from cancers that originate there and cancers that spread to the liver from other parts of the body.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups—including white or Latino men—despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.
